Table 3.
6-Month follow-up
|
12-Month follow-up
|
|||||
---|---|---|---|---|---|---|
Estimate | SE | P | Estimate | SE | P | |
Model 1: without UP compliance | ||||||
Baseline Avoidance Measure | 0.68 | 0.02 | <0.0001 | 0.75 | 0.02 | <0.0001 |
Intervention Effect | 1.00 | 0.17 | <0.0001 | 1.74 | 0.23 | <0.0001 |
Model 2: with UP compliance | ||||||
Baseline Avoidance Measure | 0.67 | 0.02 | <0.0001 | 0.74 | 0.016 | <0.0001 |
Improvement in UP compliance | ||||||
At 6-month | 0.05 | 0.01 | 0.0002 | |||
At 12-month | 0.05 | 0.01 | <0.0001 | |||
Intervention effect | 0.96 | 0.17 | <0.0001 | 1.65 | 0.23 | <0.0001 |
Mediation effect (95% Bootstrap CI) | 0.04 (0.01, 0.07) | <.0001 | 0.09 (0.05, 0.13) | <0.0001 |
Note: Covariates included in the models were age, gender, whether participants had prior contact with PLH, profession (doctor vs. other), and province.